Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02728934 · ClinicalTrials.gov registry record
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
A clinical trial, sponsored by Janssen Scientific Affairs.
- Completed
- Registry status
- 1,279
- Enrollment target
NCT02728934: Completed study, sponsored by Janssen Scientific Affairs.
NCT02728934 is a clinical trial that has completed, run by Janssen Scientific Affairs. The registered enrollment target is 1,279 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02728934 has completed, sponsored by Janssen Scientific Affairs.
- COMPLETED
- Registry status
- 1,279 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the proportion of patients with an infusion reaction in Rheumatoid arthritis (RA) patients treated with Golimumab Intravenous (IV) or Infliximab.
Primary Outcome
An infusion reaction is any adverse event that occurs during an infusion or within 1 hour of completion of infusion of either Golimumab IV or Infliximab. The number of patients with infusion reactions will be reported.
Interventions
- BIOLOGICAL Infliximab
- BIOLOGICAL Golimumab Intravenous (IV)
- BIOLOGICAL Biosimilar Infliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,279 participants |
| Start Date | 2016-02-25 |
| Est. Completion | 2020-01-31 |
What the finished NCT02728934 record still lists
NCT02728934 is an observational study that tracks outcomes without assigning an intervention. Its 1,279 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 3 interventions - of which Infliximab is the first listed.
NCT02728934 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02728934 about?
NCT02728934 is a clinical study titled "Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis". The purpose of this study is to compare the proportion of patients with an infusion reaction in Rheumatoid arthritis (RA) patients treated with Golimumab Intravenous (IV) or Infliximab.
What is the current status of trial NCT02728934?
This trial is currently completed. The enrollment target is 1,279 participants. The study started on 2016-02-25. Estimated completion is 2020-01-31.
What interventions are being tested in trial NCT02728934?
The interventions under investigation include: Infliximab (BIOLOGICAL), Golimumab Intravenous (IV) (BIOLOGICAL), Biosimilar Infliximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02728934?
This trial is sponsored by Janssen Scientific Affairs, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03970447 · 1,280 participants · Phase 2
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- NCT06468228 · 1,280 participants · Phase 3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
- NCT07207811 · 1,280 participants · Phase 3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
- NCT07001800 · 1,276 participants · Phase 2
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI